The development of therapeutic targeting strategies towards CatS is of particular interest to numerous drug companies and several clinical trials are currently underway evaluating the efficacy of such compounds in diseases such as rheumatoid arthritis, neuropathic pain and psoriasis [32]. The gene discussed is PIMREG; the disease is rheumatoid arthritis.